Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr;7(3):249-251.
doi: 10.1016/j.jaccao.2025.03.001.

Outcomes and Predictors of Severity of Immunotherapy-Related Myocarditis

Dame Idossa  1 , Joerg Herrmann  2 , Kathryn J Ruddy  3
Affiliations
Editorial

Outcomes and Predictors of Severity of Immunotherapy-Related Myocarditis

Dame Idossa et al. JACC CardioOncol. 2025 Apr.
No abstract available

Keywords: cardiac magnetic resonance; echocardiography; heart failure; immunotherapy; myocarditis.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Herrmann has participated in consulting and advisory board activities for Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
See this image and copyright information in PMC

Comment on

  • doi: 10.1016/j.jaccao.2025.01.020

Similar articles

See all similar articles

References

    1. Baik A.H., Oluwole O.O., Johnson D.B., et al. Mechanisms of cardiovascular toxicities associated with immunotherapies. Circ Res. 2021;128(11):1780–1801. - PMC - PubMed
    1. Esfahani K., Roudaia L., Buhlaiga N., et al. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27(suppl 2):S87–S97. - PMC - PubMed
    1. Tawbi H.A., Schadendorf D., Lipson E.J., et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386(1):24–34. - PMC - PubMed
    1. Haslam A., Gill J., Prasad V. Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs. JAMA Netw Open. 2020;3(3) - PMC - PubMed
    1. Hu J.R., Florido R., Lipson E.J., et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854–868. - PMC - PubMed

Publication types

LinkOut - more resources